In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

A case of unusual heart failure?

The Clinical case of the month: July 2009

A 55 year old lady of Greek ancestry was referred to Cardiomyopathy Clinic because of progressive heart failure.
Myocardial Disease

She was well till March 2008 when she presented with lower extremity edema, shortness of breath, fatigue, anorexia, hair loss and weight loss. Her patient's medical history was unremarkable except for cholecystectomy and chronic venous insufficiency. There was no family history of cardiomyopathy, heart failure or sudden cardiac death. She had 5 siblings one of whom suffered from rheumatoid arthritis.

The clinical course was characterized by rapid deterioration. A diagnosis of hypothyroidism was established and thyroxin therapy initiated. Serum iron and markers of inflammation were negative. She did not tolerate beta blocker or ACE inhibitors because of hypotension. The patient initially responded to diuretic therapy but within several months developed bilateral pleural effusions and ascites. The clinical course was complicated by gout requiring steroid therapy.

On presentation LVEF was reported as 50% but echocardiography from December 2008 showed LV wall thickening, moderate to severe systolic dysfunction (LVEF 30-35%), right ventricular hypertrophy with moderately reduced systolic function, bi-atrial enlargement and restrictive LV filling.
Coronary angiography was normal. Right heart catheterization: PA 48/24 mean 32 mmHg, PA wedge 22, LVEDP 25 and mean RA 24 mmHg. After Congo-Red staining of rectal biopsy was negative, a tentative diagnosis of idiopathic restrictive cardiomyopathy was established.

In May 2009 the patient was in NYHA functional class IV. Her ECG is demonstrated in figure 1.  An echo-doppler study showed left ventricular hypertrophy (13mm), LVEF 20%, severe diastolic dysfunction, severe right ventricular dysfunction with dilated inferior vena cava, mild tricuspid regurgitation, normal estimated pulmonary artery pressure and small pericardial effusion (figure 2-5). Cardiac MRI was performed, demonstrating a diffuse late gadolinium enhancement (LGE), more pronounced in the subendocardium (figure 6-7). A diagnostic test was performed.

 Figure 1   Figure 2  

Figures 3 & 4

Figures 5, 6 & 7

What do you think is the diagnosis in this patient, which further investigations should be performed?

Diagnosis, case resolution and treatment

Free light chains were measured in serum to find LAMBDA Free Light Chain (FLC) level of 263 mg/l (normal 6-26) with reduced F-KAPPA/F-LAMBDA ratio, compatible with Plasma Cell Dyscrasia. Bone marrow biopsy revealed 10% CD-138 positive plasma cells.

The echocardiographic features comprising a hypertrophic, non-dilated left ventricle with severe diastolic dysfunction and rapidly progressive contractile failure are compatible with an infiltrative disease. In the light of the above, the late gadolinium enhancement (LGE) pattern demonstrated on MRI is highly suggestive of cardiac amyloidosis. A diagnosis of amyloidosis was therefore established and the patient was referred to chemotherapy.

The gold standard for diagnosing cardiac amyloidosis still requires a positive Congo Red stain from endomyocardial biopsy or from another tissue in the presence of compatible cardiac morphology and physiology (1,2).

Except for certain geographic regions, the most common type of cardiac amyloidosis is AL, caused by deposition and toxicity of the amyloid in the myocardium. The introduction of a serological test for FLC greatly enhanced the work-up of patients suspected to suffer from amyloidosis. The association with plasma cell dyscrasia: either primary amyloidosis (the majority) or multiple myeloma (the minority) is obvious. FLCs are elevated in 80-90% of patients with cardiac amyloidosis (3). FLC may not be detectable in a minority with a low-level secretion who suffer from a more indolent but still lethal disease. On the other hand, the mere presence of monoclonal immunoglobulin or light chain elevation cannot be accepted as diagnostic of amyloidosis because of it presence in up to 1% of normal elderly population.

Bone marrow, subcutaneous fat pad or rectal biopsy is the preferred mode of tissue diagnosis, in particular when systemic involvement is suspected. However, Congo Red staining itself is not without limitations. Because amyloid deposits may have  a patchy distribution, in particular in the initial stage, Congo Red stain of endomyocardial biopsy may be negative due to a sampling error. It also may be negative in the Light Chain Deposition Disease, in particular type KAPPA, where FLCs do not create the classical -sheet layers. Typical extra cellular fibrillar deposits can be detected by an electron microscopic examination even when Congo Red is negative, and therefore a sample in glutaraldehyde should be a routine part of endomyocardial biopsy (1).

Cardiac MRI is a relatively new technique where a distinct pattern of diffuse LGE is found in up to 80% of cardiac amyloidosis patients but is rather rare in other cardiomyopathies (4,5). We therefore believe that a combination of echo-doppler suggestive of infiltrative cardiomyopathy, monoclonal FLC elevation along with typical MRI findings may be diagnostic of amyloidosis even when Congo Red stain is negative/non-available. In our case we considered endomyocardial biopsy to be risky because of advanced conduction disease (see ECG) but were completely confident in the diagnosis established by non-invasive criteria.


A patient with cardiac amyloidosis and heart failure should be treated with Melphalane/Steroids or Bortezomib to suppress the light chain production (6,7). Lenalidomide is an option; Thalidomide is usually poorly tolerated by amyloidosis patients with cardiac involvement (8). High dose chemotherapy and autologous bone marrow transplantation is reserved for younger patients without severe cardiac involvement (wall thickness < 15mm, preserved systolic function, no heart failure and no 'low voltage' on ECG). Its long-term advantage over conventional chemotherapy remains to be demonstrated (6,9). The issue of cardiac transplantation is highly controversial, but this option might be considered in isolated cardiac amyloidosis with no other organ involvement and when FLC levels may be reduced to normal with therapy and/or ensuing bone marrow transplantation (10).


1. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005;112:2047-60.
2. Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol. 2007;50:2101-10
3. Bochtler T, Hegenbart U, Heiss C, et al., Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. Haematologica. 2008;93:459-62.
4. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111:186-93
5. Vogelsberg H, Mahrholdt H, Deluigi CC, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol. 2008;51:1022-30.
6. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357:1083-93.
7. Kastritis E, Anagnostopoulos A, Roussou M, et al., Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica. 2007;92:1351-8.
8. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007;109:465-70.    
9. Kristen AV, Perz JB, Schonland SO, et al., Non-invasive predictors of survival in cardiac amyloidosis. Eur J Heart Fail. 2007;9:617-24.
10. Sack FU, Kristen A, Goldschmidt H, Schnabel PA, Dengler T, Koch A, Karck M. Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis. Eur J Cardiothorac Surg. 2008;33:257-62.

Notes to editor

By Dr. Michael Arad, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Israel.
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.

Contact us

Working Group on Myocardial & Pericardial Diseases

European Society of Cardiology

European Heart House
Les Templiers
2035 Route des Colles
CS 80179 BIOT

06903Sophia Antipolis, FR